United States securities and exchange commission logo





                            March 8, 2021

       Eyal Barad
       Chief Executive Officer
       Cannabics Pharmaceuticals Inc.
       # 3 Bethesda Metro Center, Suite 700
       Bethesda, MD 20814

                                                        Re: Cannabics
Pharmaceuticals Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed January 27,
2021
                                                            File No. 333-252454

       Dear Mr. Barad:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       About this Prospectus, page 3

   1.                                                   We note your response
to prior comment 1. Please disclose how you determined that a
                                                        multiplier of 300% of
the shares issuable upon conversion of the notes was a good faith
                                                        estimate of the maximum
number of shares that may be issued.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

              Refer to Rules 460 and 461 regarding requests for acceleration.
Please allow adequate
       time for us to review any amendment prior to the requested effective
date of the registration
       statement.
 Eyal Barad
Cannabics Pharmaceuticals Inc.
March 8, 2021
Page 2

      You may contact Dillon Hagius at 202-551-7967 or Celeste Murphy at
202-551-
3257 with any other questions.



                                                       Sincerely,
FirstName LastNameEyal Barad
                                                       Division of Corporation
Finance
Comapany NameCannabics Pharmaceuticals Inc.
                                                       Office of Life Sciences
March 8, 2021 Page 2
cc:       Steve Kronengold, Esq.
FirstName LastName